"megadose oral methylprednisolone methylprednisolone Multiple Sclerosis" Channels
BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.
Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html
Interested? Contact priority@bioportfolio.com
Showing "megadose oral methylprednisolone methylprednisolone Multiple Sclerosis" Channels 1–25 of 81
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the entire immune system, and thus restore immunological bal...
Amyotrophic lateral sclerosis ALS
Lemtrada (alemtuzumab) is being developed by Sanofi in collaboration with Bayer Healthcare for the treatment of relapsing multiple sclerosis.
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
Proliferation inducing ligand APRIL
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
Primary lateral sclerosis and progressive pseudobulbar palsy
B cell activating factor of the TNF family BAFF
Treatment of inflammatory and autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis.
Multiple Chemical Sensitivity Syndrome
Multiple Endocrine Neoplasia MEN Syndromes
Multiple Endocrine Neoplasia Type 1 MEN 1
